Blood test to monitor advanced cancer treatment response
Part of Cancer clinical trials.
This study looks at whether a simple blood test (called liquid biopsy) can help monitor how well your cancer treatment is working. By checking for tumor DNA in your blood before and during treatment, researchers hope to see if the treatment is effective and if the cancer is responding, which could help guide your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced cancer (cancer that has spread or is hard to treat).
- You must be able to understand and sign a consent form, which also includes agreeing to store samples in a biobank for future research.
- You must have already had or be scheduled for tumor-normal sequencing (a genetic test of your tumor compared to your normal DNA), usually done through a Molecular Tumor Board (a team that reviews genetic test results to guide treatment).
- You must have received a treatment recommendation from the Molecular Tumor Board.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a blood test can find tumor genetic changes (called “plasma genomic profiling”) to help choose the best next treatment. It may help your care team decide therapy after your cancer progresses or seems likely to progress soon.
This study uses a blood test (liquid biopsy) to look for tumor DNA in patients with advanced cancer. It aims to see if this test can help doctors monitor the cancer and make better treatment decisions.
This study uses a simple blood test to look at the genetic makeup of your tumor. The results may help your doctors choose the best treatment for you. You will need to provide a tumor sample or have a biopsy.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This study measures “circulating tumor markers,” meaning substances from cancer that can show up in blood, to better understand how cancer is doing after treatment. You may join if you recently received cancer care at a participating center and meet basic study and follow-up requirements.
This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.
Hear when a new Next-Generation-Sequencing trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.